

Novel therapeutic strategies in the treatment of triple-negative breast cancer

Karima Oualla, Heba M. El-Zawahry, Banu Arun, James M. Reuben, Wendy A. Woodward, Heba Gamal El-Din, Bora Lim, Nawfel Mellas, Naoto T. Ueno and Tamer M. Fouad

Abstract: Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Treating patients with TNBC remains clinically challenging, as patients are not candidates for endocrine or HER2-directed therapy. As a result, chemotherapy with traditional agents such as anthracyclines and taxanes remains the only available option with moderate success. Recent discoveries have revealed that TNBC is a heterogeneous disease at the clinical, histological and molecular levels. The use of biomarkers to identify distinct subsets of TNBC that derive the greatest benefit from presently approved as well as novel therapeutics has become the main focus of current research. The aim of this review is to explore the clinical and biological complexity of TNBC as well as identify novel therapeutic options that target the various molecular subsets of TNBC.

Keywords: chemotherapy, clinical trials, immunotherapy, molecular subtypes, targeted therapies, triple-negative breast cancer

Received: 8 December 2016; accepted in revised form: 27 April 2017.

Overview

Triple-negative breast cancer (TNBC) is a unique subset of breast cancer that is characterized by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. It accounts for approximately 15–20% of all breast cancer diagnoses,¹ and has been characterized by an aggressive natural history and poor survival compared with other breast cancers. Distant recurrences peak early at 3 years following diagnosis and a majority of deaths occur in the first 5 years after initial diagnosis.²

In the absence of new targeted therapies, conventional chemotherapy remains the mainstay of treatment with suboptimal outcomes. Recent discoveries have revealed that TNBC is a heterogeneous disease entity at the clinical, histological and molecular levels. Advanced technologies, such as next generation sequencing, have led to the identification of several molecular characteristics including the inactivation of the BRCA pathway, MAP/ERK kinase (MEK) and Phosphatidylinositol-3-Kinase (PI3K)

pathway activation, high rates of Tumor Protein p53 (TP53) mutation, high activation of MYC, loss of retinoblastoma protein (RB1), enrichment for androgen receptor (AR) and the AR gene.^{1,3,4} In addition, several potentially targetable amplifications or deletions, including immune checkpoints Programmed Death-1 (PD1) and Programmed death-ligand 1 (PDL1), have also been identified.⁵ These molecular features have allowed the development of promising therapeutic agents such as DNA-damaging agents, AR inhibitors and immune checkpoint inhibitors.

The objective of this article is to review the ongoing effort to identify subsets of TNBC as well as explore the promising therapeutic strategies that target them.

The clinical heterogeneity of TNBC

At the clinical level, some patients do very well, while the majority of patients have very poor outcomes. Compared with other breast cancer subtypes, TNBC is highly aggressive with less

Ther Adv Med Oncol
2017, Vol. 9(7) 493–511
DOI: 10.1177/
1758834017711380
© The Author(s), 2017.
Reprints and permissions:
[http://www.sagepub.co.uk/
journalsPermissions.nav](http://www.sagepub.co.uk/journalsPermissions.nav)

Correspondence to:
Tamer M. Fouad
Department of Medical
Oncology, The National
Cancer Institute, Cairo
University, Kasr El-Aini
Road, Cairo, 11796, Egypt
tamer.fouad@nci.cu.edu.eg

Karima Oualla
Medical Oncology
Department, Hassan II
University Hospital, Fes,
Morocco

Heba M. El-Zawahry
Department of Medical
Oncology, The National
Cancer Institute, Cairo
University, Cairo, Egypt

Banu Arun
Department of Breast
Medical Oncology, The
University of Texas MD
Anderson Cancer Center,
Houston, TX, USA

James M. Reuben
Department of
Hematopathology, The
University of Texas MD
Anderson Cancer Center,
Houston, TX, USA

Wendy A. Woodward
Department of Radiation
Oncology, The University
of Texas MD Anderson
Cancer Center, Houston,
TX, USA

Heba Gamal El-Din
Department of Surgical
Oncology, The National
Cancer Institute, Cairo
University, Cairo, Egypt

Bora Lim
Department of Breast
Medical Oncology, The
University of Texas MD
Anderson Cancer Center,
TX, USA

Nawfel Mellas
Medical Oncology
Department, Hassan II
University Hospital, Fes,
Morocco

Naoto T. Ueno
Department of Breast
Medical Oncology, The
University of Texas MD
Anderson Cancer Center,
TX, USA

favorable outcomes in terms of likelihood of progression, available therapeutic options and overall survival (OS). It affects more often women under 40 years of age with higher incidence among African American and Hispanic women compared with other breast cancer subtypes.^{6–9}

Neoadjuvant studies have suggested that women with TNBC are more sensitive to initial anthracyclines and taxanes compared with other breast cancer subtypes, with clinical response rates of up to 85% and pathologic complete response (pCR) rates of 30–40%.¹⁰ Although patients who achieve a pCR have a better prognosis, the vast majority of patients with TNBC have residual disease after preoperative chemotherapy and usually present with rapid disease progression in the following 3–5 years.^{11–15} To date there are no predictive factors that identify subsets of patients with TNBC who will ultimately achieve pCR.

Triple negative tumors present a distinctive pattern of relapse, with a higher risk of developing distant metastasis and death compared with other breast cancer subtypes.^{16–19} These tumors have a predilection for visceral, lung and brain metastasis compared with luminal breast cancers that favor relapses in bone and skin.^{20–22} Harrell and colleagues reported a higher incidence of brain and lung metastases in basal-like (BL) and claudin-low breast tumors (both commonly triple negative),²³ with approximately 50% of brain relapses occurring in patients with advanced TNBC.²⁴

The histologic heterogeneity of TNBC

TNBC is diagnosed immunohistochemically as breast tumors that do not overexpress ER, PR or HER2. However, the cut off used to define estrogen and PR negativity has changed over time, resulting in a discordance in the definitions used in the literature (<10% versus <1%). The current definition established by the American College of Pathology, the American Society of Clinical Oncology and the St Gallen guidelines, recently used a cut off of less than 1% to define estrogen and progesterone negative tumor; whereas, HER2 negativity is defined as either immunohistochemistry (IHC) expression of 0–1+ or lack of gene amplification (Fluorescence In Situ Hybridization (FISH), 2.0).^{25–27}

Consequently, endocrine therapy is currently prescribed for patients with ER expression of at least 1% in all stages of breast cancer. This has resulted in a subset of patients (ER expression 1–10%)

who were previously considered ER negative but who under the current recommendations would receive endocrine therapy.

The large majority of TNBC tumors are invasive ductal carcinomas characterized by high histologic grade, poor differentiation, central necrosis, high lymphocytic infiltrate and high proliferation rates.^{12,13} In addition, several other high-grade histologic subtypes of breast cancer including medullary carcinoma, metaplastic carcinoma, adenoid cystic carcinoma and apocrine/histiocytoid carcinoma present with the TNBC phenotype.^{28–32}

Molecular heterogeneity of TNBC

Molecular profiling has confirmed the heterogeneous nature of TNBC that had already been observed from its clinical behavior. The Cancer Genome Atlas (TCGA) Research Network analyzed primary breast cancers using six platforms, including genomic DNA copy number arrays, messenger RNA arrays, exome sequencing, DNA methylation, microRNA sequencing, and reverse-phase protein arrays.⁴ The most frequent genetic alterations were found in DNA damage-repair genes, including loss of TP53, RB1 and BRCA1 in addition to activation of the PI3K pathway.

It is important to understand the difference between TNBC and the BL phenotype because TNBC is frequently assimilated into the BL molecular phenotype, although these two breast cancer subtypes are not synonymous.

In reality, 75–80% of TNBCs display a BL molecular phenotype on gene expression arrays, and it is identified by a basal epithelial cell gene expression cluster, including high-molecular-weight basal cytokeratin 5/6 (CK5/6), CK14, CK17, epidermal growth factor receptor (EGFR), HER1, B crystallin, vimentin, laminin, integrin-b4, fascin, caveolin 1/2 (CAV1/2), c-Kit, and P-cadherin. Similarly, not all BL tumors are TNBC; and up to 54% of BL cancers do not present the immuno-histochemical phenotype of TNBC.^{33,34}

Both BL breast cancer and TNBC show an important overlap with BRCA1-mutated tumors. The prevalence of BRCA1 or two mutations in TNBC is estimated to be between 10% and 20%,³⁵ and these mutations play a major role in DNA repair as tumor suppressor genes. This specific genomic instability in BRCA-1 carriers may provide specific therapeutic opportunities in

TNBC. Given the limited clinical usefulness of the BL molecular phenotype, the best strategy is to identify BL tumors using an immunohistochemistry panel of antibodies (ER, HER2, CK5/6 and EGFR HER1).^{36,37}

Other molecular markers, that may be targetable, have also been identified by differential gene expression, including several amplifications and deletions.^{33,38} Common amplifications include PIK3CA (49%), KRAS (32%), VEGFR (>30%), BRAF (30%), EGFR (23%) whereas less frequent ones include KIT, MET, FGFR1, FGFR2, PDGFRA and IGF1R.⁴ Deletions were also observed in PTEN, INPP4B in addition to deletion of chromosome 5q13–14, which harbors the RASA1 gene and regulates the RAS oncogene.^{39–43}

Distinct intrinsic subtypes of TNBC were identified using gene expression and sequencing tools. The study by Lehmann and colleagues analyzed 587 TNBCs by gene expression profiling and has identified six subtypes.¹ The authors identified two BL subtypes (BL1 and BL2), mesenchymal (M), mesenchymal stem-like (MSL), immunomodulatory (IM) and finally a luminal androgen receptor (LAR) with sensitivity to an AR antagonist. BL1 tumors are characterized with high expression of cell cycle and DNA damage response gene expression signatures and BL2 tumors are characterized by enrichment in growth factor signaling and myoepithelial markers. The two mesenchymal subtypes, M and MSL, are characterized by high expression of genes involved in differentiation and growth factor pathways with high sensitivity to dual PI3K/mTOR inhibition and Abl/Src inhibitor dasatinib.⁴⁴ This study fostered a major effort to discover and develop new drugs that target specific subtypes of TNBC.

Claudin-low is another less common subtype of TNBC that shows low expression of luminal differentiation markers, low expression of genes involved in tight cell junctions such as E-cadherin, intense immune infiltrate, high enrichment for epithelial-to-mesenchymal transition (EMT) markers and stem-cell-like features that may be enriched in BRCA pathway alterations.^{45,46} Response to treatment of claudin-low subtype is intermediate between luminal and BL subtypes explained by the high rate of medullary and metaplastic differentiation.

Further classification using combination copy number transcriptome analysis highlights the heterogeneity of TNBC tumors.^{47,48}

Therapeutic approaches to TNBC

In the absence of new approved targeted therapies, standard chemotherapy is still the mainstay of treatment. The heterogeneity of TNBC has made it difficult to treat unselected patients. As a result there is an ongoing effort to develop more specific targets, and several new targeted treatments and immunotherapeutic drugs are under development.

DNA-damaging chemotherapy and DNA repair targets

DNA repair mechanisms play a major role in maintaining the integrity and stability of the genome. BRCA1 and BRCA2 are tumor suppressor genes that are directly involved in homologous recombination-mediated repair of double-stranded breaks. Defects in BRCA1 or BRCA2 genes result in impaired DNA repair by homologous recombination and subsequent genomic instability.^{49,50}

As a result, women with germline mutations in these genes are predisposed to hereditary cancer syndromes, including breast and ovarian cancers. Breast cancers arising in BRCA1 germline mutation carriers display a triple-negative phenotype in more than 75% of cases.^{51,52} Understanding DNA repair mechanism defects has allowed the development of new therapeutic approaches in TNBC due to their higher sensitivity to DNA-damaging agents, including platinum salts and poly ADP-ribose polymerase (PARP) inhibitors.

However, sporadic breast cancers have also been associated with various genetic and epigenetic disruptions to BRCA function, leading to impaired homologous repair. These sporadic breast cancers share various phenotypic characteristics with familial BRCA cancers, a concept that has been termed ‘BRCAness’.^{53–56}

Optimal use of platinum salts in TNBC

Platinum salts are non-cell-cycle-specific agents that bind with DNA to form intrastrand crosslinks, thus affecting DNA replication and subsequently inducing apoptosis in cancer cells. The addition of platinum salts to the treatment of TNBC in the neoadjuvant and metastatic setting stems from its proclaimed role in TNBC associated with BRCA1 mutation.

Neoadjuvant setting

Studies involving the addition of platinum compounds in the neoadjuvant setting have reported conflicting results. In the GeparSixto trial the addition of weekly carboplatin to neoadjuvant paclitaxel, liposomal doxorubicin, and bevacizumab improved pCR rates in a subset of patients with TNBC from 36.9% to 53.2% ($p = 0.005$), but at the cost of higher toxicity-associated treatment discontinuation.⁵⁷ Recently, an improvement in survival was reported for patients receiving carboplatin in this trial, with a significant increase in 3-year disease-free survival (DFS) from 76.1% to 85.8% [hazard ratio (HR) 0.56; 95% confidence interval (CI) 0.33–0.96; $p = 0.035$].⁵⁷ It should be noted that the GeparSixto trial showed better outcomes in patients with TNBC with the addition of carboplatin, independently of germ-line BRCA status.

These results were supported by The Cancer and Leukemia Group B study (CALGB 40603), a two-by-two factorial randomized phase II trial of 454 patients with stage II and III TNBC evaluating weekly paclitaxel with or without carboplatin or bevacizumab followed by dose dense doxorubicin plus cyclophosphamide. The addition of carboplatin resulted in improved pCR rates both for the breast alone from 46% to 60% (odds ratio 1.76; $p = 0.0018$) and for the breast/axillae from 41% to 54% (odds ratio 1.71; $p = 0.0029$) but not in terms of DFS or OS.⁵⁸

Patients with TNBC who do not achieve pCR after neoadjuvant chemotherapy have a significantly worse prognosis. Unfortunately not all trials evaluating the role of platinum compounds have demonstrated improvements in pCR.⁵⁹

In conclusion, although the incorporation of carboplatin has typically been considered in patients with locally advanced disease, especially in the setting of BRCA-associated TNBC, its clinical use remains controversial because of significant treatment-related toxicity and unclear long-term benefits. As a result, current National Comprehensive Cancer Network (NCCN) guidelines do not recommend the use of platinum-based agents in the neoadjuvant or adjuvant setting outside of a clinical trial.⁶⁰ However, several ongoing trials may provide additional information on long-term outcomes as well as on their potential use in the neoadjuvant and adjuvant setting. A phase III trial (EA1131) randomizes patients presenting TNBC with residual disease after neoadjuvant chemotherapy to four

cycles of platinum chemotherapy or observation [ClinicalTrials.gov identifier: NCT02445391]. Another phase III trial (NRG BR003) is evaluating adjuvant doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin among patients with node-positive or high-risk TNBC [ClinicalTrials.gov identifier: NCT02488967].

Metastatic setting

Similarly platinum compounds were evaluated in the metastatic setting with conflicting results. A prospective phase II study evaluated cisplatin and carboplatin in patients with metastatic TNBC with an overall response rate (ORR) of 25.6%. However, this rate was significantly increased to 54.5% in patients with germ-line BRCA1/2 mutations. The study also showed that patients who presented elevated values of homologous recombination deficiency (HRD) assays that characterize BRCA-like genomic instability also had better response to platinum-based treatments, despite the absence of germ-line BRCA1/2 mutations.⁶¹

A phase II trial, comparing docetaxel and cisplatin *versus* docetaxel and capecitabine showed the superiority of docetaxel plus cisplatin in the first-line treatment of patients with metastatic TNBC in terms of both ORRs (63.0% *versus* 15.4%; $p = 0.001$) and progression-free survival (PFS) (10.9 *versus* 4.8 months; $p = 0.001$).⁶² Another randomized, open-label, multicenter, phase III trial enrolling 240 patients with TNBC was designed to test the noninferiority of gemcitabine plus cisplatin to gemcitabine plus paclitaxel. Results showed that the cisplatin arm was noninferior to and superior to the comparator [PFS: HR 0.692; 95% CI 0.523–0.915; $p = 0.0001$ (noninferiority) and $p = 0.009$ (superiority)].⁶³

In contrast, a large phase III trial ‘the Triple Negative Breast Cancer Trial’ (TNT) randomized 376 patients with metastatic TNBC to receive either carboplatin or docetaxel as first-line treatment with crossover in the case of progression. In unselected patients, the primary endpoint of objective response was not met in both situations: up front (31.4% *versus* 35.6%; $p = 0.44$) and following crossover (22.8% *versus* 25.6%; $p = 0.73$). Similar results were obtained for PFS (4.5 *versus* 3.1 months) and OS (12.3 *versus* 12.4 months) for the docetaxel and carboplatin arm, respectively.⁶⁴ However, BRCA-mutant carriers in the carboplatin arm showed a significantly higher response

compared with the docetaxel arm (68% *versus* 33.3%; 95% CI 6.3–63.1; $p = 0.03$). Moreover, the median PFS for patients with BRCA1/2 mutations in the carboplatin arm was 6.8 months compared with 3.1 months for non-BRCA mutation carriers, and 4.8 months and 4.6 months, respectively, among patients with and without BRCA1/2 mutations treated with docetaxel.⁶⁴

The use of platinum appears to be an important therapeutic option in the metastatic setting, where treatments are mainly palliative due to the lack of specific standards for TNBC but even more so in patients who are BRCA positive.

PARP inhibitors. PARP enzymes play a major role in DNA repair mechanisms, specifically in homologous recombination-mediated repair of double-stranded breaks. Any reduction in their activity leads to persistent DNA lesions that subsequently induce apoptosis. As a result, inhibitors of PARP enzymes were developed to target vulnerable cancers with specific DNA-repair deficiency, including TNBC with BRCA1/2 mutations and TNBC with BRCAness phenotype.

Several trials tested the role of PARP inhibitors alone or in combination with chemotherapy in different settings (Table 1). Olaparib is an orally active PARP inhibitor that has an impressive response rate and favorable toxicity. A phase II study assessed the efficacy, safety, and tolerability of olaparib in women with BRCA1 or BRCA2 mutations and advanced breast cancer. Patients were assigned to two sequential cohorts. The first cohort ($n = 27$) was given continuous oral olaparib at the maximum tolerated dose (400 mg twice daily), and the second ($n = 27$) was given a lower dose (100 mg twice daily). Overall responses ranged from 22% (100 mg twice per day) to 41% (400 mg twice per day) with favorable toxicity.⁶⁵ Other ongoing phase III trials are evaluating the use of olaparib in the neoadjuvant [ClinicalTrials.gov identifier: NCT02032823] and metastatic setting [ClinicalTrials.gov identifier: NCT02000622] for patients with mutations in BRCA.

Another putative PARP inhibitor, iniparib, was evaluated in an open-label, phase II trial of 123 patients with metastatic TNBC who were randomly assigned to receive gemcitabine/carboplatin with or without iniparib.⁶⁶ Patients who received iniparib had significant improvement in the form of a higher clinical benefit rate (CBR) (55.7% *versus* 33.9%) and ORR (52.5% *versus*

32.3%) in addition to a survival benefit: PFS from 3.6 to 5.9 months (HR 0.59; $p = 0.012$) and OS from 7.7 to 12.3 months (HR 0.57; $p = 0.014$).⁶⁶ Based on these impressive results, a phase III study was conducted to evaluate iniparib using the same design.⁶⁷ Unfortunately, there was no statistical benefit in terms of PFS and OS. These poor results were explained in part due to its original misclassification as a PARP inhibitor, and the subsequent discovery that iniparib lacked PARP activity.^{68,69}

In the neoadjuvant setting, a single-arm phase II trial has showed an important response rate, with iniparib especially in BRCA1/BRCA2 carriers.⁷⁰ Similarly, the addition of veliparib and carboplatin to standard neoadjuvant chemotherapy produced an improvement in pCR for patients with TNBC from 26% to 52%, but it is difficult to extract the benefit of veliparib from the benefit of carboplatin.⁷¹

The BROCADE trial is another randomized phase II study that evaluated the efficacy and tolerability of veliparib in combination with carboplatin and paclitaxel *versus* placebo in patients presenting with locally advanced or metastatic BRCA1/BRCA2-mutant breast cancer, with 42.4% of patients who had TNBC.⁷² The ORR was 77.8% (95% CI 66.4–86.7) in the veliparib arm compared with 61.3% (95% CI 49.7–71.9) in the placebo group. The improvement in PFS in the veliparib arm (14.1 *versus* 12.3 months) was not statistically significant. The trend towards improved median survival observed with veliparib was also not statistically significant (28.3 *versus* 25.9 months; $p = 0.157$).⁷² These results can be explained by the small number of patients and an ongoing phase III trial is more adequately powered to address this issue [ClinicalTrials.gov identifier: NCT02163694].

Talazoparib is a novel, dual-mechanism PARP inhibitor that potently inhibits the PARP enzyme and effectively traps PARP on DNA. The phase I trial [ClinicalTrials.gov identifier: NCT01286987] showed an important single-agent antitumor activity in BRCA-mutated breast cancer (ORR 33%).⁷³ A phase II trial is evaluating the activity of talazoparib in patients with BRCA1/2 wild-type breast cancer using an optimal Simon two-stage design. Patients will be assigned to one of two parallel cohorts. The first cohort ($n = 29$) includes patients with advanced TNBC with underlying homologous recombination defects as assessed by

Table 1. Selected phase II and III clinical trials of PARP inhibitors in TNBC.

Disease setting	Study, ClinicalTrials.gov identifier, NCT00494234	Phase	Treatment	Primary endpoint
Metastatic	AZD2281 in patients with known BRCA mutation status or recurrent high-grade ovarian cancer or patients with known BRCA mutation status/TNBC, NCT00679783	II, open label, single arm	Olaparib 400 mg	ORR, CR
	Efficacy and safety of KU-0059436 (olaparib) given orally twice daily in patients with advanced BRCA1- or BRCA2-associated BC	II, open label, single arm	Olaparib 100 mg twice daily, 400 mg twice daily	ORR, CR
	Efficacy and safety of olaparib given orally twice daily in patients with advanced cancers who have a confirmed genetic BRCA1 or BRCA2 mutation, NCT01078662	II, open label, single arm	Olaparib 400 mg twice daily	ORR, CR
	Efficacy and safety of talazoparib in patients with BRCA1 and BRCA2 wild type and (1) advanced TNBC and HRD and (2) advanced HER2-negative BC with either a germline or somatic mutation in HR pathway genes, NCT02401347	II, open label, single arm	Talazoparib	ORR
	Efficacy and safety of talazoparib <i>versus</i> physician's choice (capecitabine, eribulin, gemcitabine or vinorelbine) in patients with BRCA mutation and locally advanced or metastatic BC, NCT01945775	III, open label, randomized	Talazoparib	PFS
Neoadjuvant	Safety and efficacy of the addition of veliparib plus carboplatin <i>versus</i> the addition of carboplatin to standard neoadjuvant chemotherapy <i>versus</i> standard neoadjuvant chemotherapy in subjects with early stage TNBC, NCT02032277	III, randomized, double blind	Veliparib	pCR

BC, breast cancer; CR, complete response; HRD, homologous recombination deficiency; pCR, pathological complete response; PFS, progression-free survival; ORR, objective response rate; TNBC, triple-negative breast cancer.

the HRD assay and the second cohort ($n = 29$) includes patients with advanced HER2-negative breast cancer with a somatic or germline deleterious mutation in a non-BRCA1/2 HR pathway gene. Eligible patients will receive oral talazoparib (1.0 mg/day, 28-day cycles) until disease progression or unacceptable toxicity [ClinicalTrials.gov identifier: NCT02401347].⁷⁴

An ongoing international phase III trial (EMBRACA) is comparing the safety and efficacy of talazoparib *versus* physician's choice (capecitabine, eribulin, gemcitabine or vinorelbine) in BRCA-mutation subjects with locally advanced or metastatic breast cancer. The primary objective is PFS and secondary objectives include objective response rate (ORR), OS, and safety [ClinicalTrials.gov identifier: NCT01945775] (Table 1).

Targeting growth factors. Inhibition of vascular endothelial growth factor (VEGF). VEGF is

overexpressed in TNBC and has a critical role in proliferation, invasion and metastasis. This is supported by the high proliferative potential of TNBC and has led to the incorporation of antiangiogenic treatments but with limited activity in unselected patients.

In a meta-analysis of three phase III trials of bevacizumab given as first-line therapy in the metastatic setting (E2100, AVADO, RIBBON-1), a pooled analysis of 621 patients with TNBC demonstrated a significant benefit in terms of median PFS (8.1 *versus* 5.4 months), but not OS.⁷⁵ Similar findings were observed in second-line therapy in a subgroup analysis of the RIBBON-2 study, in which bevacizumab showed a benefit in PFS among the TNBC subgroup (6.0 *versus* 2.7 months for chemotherapy alone; $p = 0.0006$) but without statistically significant advantage in OS.⁷⁶ After mature survival results became available, bevacizumab lost its regulatory approval in metastatic breast cancer in the United States, but

continues to be used in other countries.^{60,77} In the neoadjuvant setting, the GeparQuinto showed high rates of pCR when bevacizumab was added to anthracycline/taxane-based chemotherapy, but these findings were not confirmed in the NSABP B-40 trial.^{78,79} Similar disappointments followed with adjuvant trials such as the phase III BEATRICE trial in which bevacizumab failed to show an advantage in OS.⁸⁰

Regarding anti-VEGFR tyrosine kinase inhibitors such as sunitinib and sorafenib, they showed an activity in breast cancer in clinical studies with substantial TNBC populations. However, subsequent phase III trials were negative.

In a prospective and randomized phase III study, patients with advanced breast cancer were randomly assigned to receive docetaxel with or without sunitinib as a first-line treatment. Although ORR was significantly higher with the combination compared with monotherapy (55% *versus* 42%, $p = 0.001$), the PFS was not different ($p = 0.265$) and adverse events were also more common with the combination.⁸¹

A randomized phase III trial (SUN 1107) evaluated single-agent sunitinib *versus* single-agent capecitabine for the treatment of patients with advanced breast cancer after failure of standard treatment, with the primary endpoint of prolonging PFS. The data showed an inferior outcome for the sunitinib *versus* the capecitabine group. The median PFS was 2.8 *versus* 4.2 months and median OS was 15.3 *versus* 24.6 months. Based on these results, the study was thought to be futile and discontinued early.⁸²

Sorafenib was also evaluated in several trials. A phase II trial, demonstrated that the combination of sorafenib and capecitabine improved PFS in patients with advanced HER2-negative breast cancer (median 6.4 *versus* 4.1 months; HR 0.58; 95% CI 0.41–0.81; $p = 0.001$).⁸³ These results led to a phase III confirmatory study (RESILIENCE trial) in which 537 women with locally advanced or metastatic HER2-negative breast cancer who had received no more than one prior regimen were enrolled.⁸⁴ The trial excluded women previously treated with a VEGF receptor inhibitor. Patients received capecitabine at 1000 mg/m² twice daily plus sorafenib or placebo 600 mg/day. The study did not meet its primary endpoint, with a median PFS of 5.5 months with the combination of capecitabine

and sorafenib *versus* 5.4 months for capecitabine plus placebo (HR 0.973; $p = 0.406$). Median OS was not improved (18.9 *versus* 20.3 months; HR 1.195; $p = 0.930$).⁸⁴

Inhibition of EGFR. Overexpression of EGFR is well established in TNBC and was reported in over 50% of cases. Although EGFR plays an important role in proliferation and migration, only limited activity was seen with monoclonal antibodies against EGFR.⁸⁵ These disappointing results suggested a lack of correlation between EGFR overexpression and the activity of EGFR inhibitors in TNBC.

Patients with TNBC treated with the EGFR inhibitor cetuximab in addition to cisplatin in the phase III trial (BALI-1) reported improved ORR of 20% compared with 10% for those who received cisplatin alone, but the difference was not statistically significant. PFS was also improved from 1.5 to 3.7 months but with non-negligible toxicity, mainly in the form of rash and neutropenia.⁸⁶

Another EGFR inhibitor, panitumumab, was investigated in a single-arm phase II clinical trial including 14 patients with locally advanced and metastatic TNBC, evaluating the combination of weekly paclitaxel, carboplatin and panitumumab. The ORR of the 13 evaluable patients was 46%, while the median time to best response was 2.4 months and the median time to disease progression was 3.6 months.⁸⁷

A more recent phase II trial evaluated panitumumab among 71 women with metastatic TNBC in addition to carboplatin and gemcitabine. The median PFS was 4.4 months (95% CI 3.2–5.5 months) with a median follow up of 11 months and the ORR was 42%. Reported toxicity was mainly in the form of rash (70%), fatigue (52%), neutropenia (45%) and thrombocytopenia (45%).⁸⁸

Inhibition of FGFR. FGFR1 is amplified in TNBC in approximately 9% of tumors and FGFR2 in 4%.⁸⁹ Both of them have a critical role in differentiation, proliferation, resistance to apoptosis and metastasis. Their implication in the cancer process makes them an interesting target for development of new personalized treatments.⁸⁹ To date, there is no study evaluating FGFR inhibitors in TNBC but there is an ongoing phase II, randomized study of lucitanib in patients with FGF

aberrant metastatic breast cancer when patients with TNBC were eligible [ClinicalTrials.gov identifier: NCT02202746].

Inhibition of the PI3K/AKT/mTOR pathway. The PI3K/AKT signaling pathway is hyperactivated in approximately 10% of patients with TNBC, and various oncogenic alterations may occur in this pathway, including PIK3CA mutations, loss of the tumor suppressor phosphatases inositol polyphosphate 4-phosphatase type II (INPP4B) and loss of PTEN in addition to amplification of AKT and translocation of AKT3.^{1,90}

A small phase II neoadjuvant study including 50 patients with TNBC evaluated the addition of everolimus to weekly paclitaxel followed by anthracycline-based chemotherapy. The everolimus arm was associated with an improved clinical response rate (48% versus 30%), but this was not statistically significant and no benefit was noted in terms of pCR rate.⁹¹

An ongoing randomized phase II trial is testing the efficacy of adding everolimus to weekly paclitaxel plus bevacizumab in the first-line treatment of patients with HER2-negative metastatic breast cancer [ClinicalTrials.gov identifier: NCT00915603], while other ongoing studies are investigating the use of everolimus in the treatment of advanced TNBC [ClinicalTrials.gov identifier: NCT01272141, NCT01111825 and NCT00827567]. The NCT01272141 trial is testing the combination of lapatinib and everolimus in locally advanced or metastatic TNBC.

Results are also awaited from trials evaluating the impact of another mTOR inhibitor temsirolimus in the neoadjuvant and metastatic settings.

The serine/threonine kinase AKT inhibitor ipatasertib is being investigated in a neoadjuvant phase II trial (FAIRLANE) evaluating the impact of adding ipatasertib to paclitaxel in patients with stage IA–IIIA TNBC [ClinicalTrials.gov identifier: NCT02301988]. Ipatasertinib is also under investigation in metastatic setting in a randomized phase II trial (LOTUS trial) in combination with paclitaxel as a first line of treatment in patients with locally advanced or metastatic breast cancer. PFS is the primary endpoint in all patients with TNBC and patients with TNBC with PTEN-low tumors [ClinicalTrials.gov identifier: NCT02162719].

PIK3CA mutation may also be a major driver for LAR TNBC cell lines. This TNBC subtype presents with a high frequency of PIK3CA-activating mutations and shows a high sensitivity to PI3K inhibitors with a synergistic effect of the AR inhibitor with a PI3K inhibitor.^{92,93} Based on these results, targeting both the AR and PI3K pathways are promising strategies that are currently under investigation.

Similarly, PI3K has an important role in the stabilization of double-strand breaks by interacting with the homologous recombination complex and creating a BRCA1/2-deficient-like state. PI3K inhibition promotes HRD by downregulating BRCA1/2 and creating a BRCA-mutant-like tumor state. This down modulation of BRCA1/2 was accompanied by concomitant activation of the extracellular signal-regulated kinase (ERK) pathway following PI3K inhibition.⁹⁴ This rationale has led to the evaluation of combined use of DNA-damaging agents with PI3K inhibitors.⁹⁵ Some studies have shown that the combinations of PI3K inhibitors and cisplatin produce additive or synergistic effect. There is also an ongoing phase I trial testing the pan ongoing PI3K inhibitor BKM120 combined with olaparib in patients with metastatic TNBC [ClinicalTrials.gov identifier: NCT01623349].

AR blockade. Approximately 10% of TNBCs are classified as the LAR subtype. This subclass is characterized by the expression of luminal gene and the enrichment for AR and the AR gene.¹ As a result, the use of antiandrogen therapy to target this subtype is currently under investigation.⁹⁶ Several trials have investigated the role of antiandrogen agents in TNBC (Table 2). A phase II multicenter study has evaluated the efficacy of an oral nonsteroidal antiandrogen, bicalutamide, in patients with metastatic AR-positive TNBC.⁹⁷ A 6-month CBR of 19% (95% CI 7–39%) was reported for bicalutamide with a median PFS of 12 weeks (95% CI 11–22 weeks). The treatment was tolerable and side effects included hot flashes, fatigue, limb edema and transaminase elevations. A newer AR inhibitor, enzalutamide, has also shown activity in AR-positive TNBC with promising results from a multicenter phase II trial conducted in two stages. In stage 1, a CBR of at least 16 weeks, which was the primary endpoint of the study, was achieved in 42% of the 26 evaluable patients who received oral enzalutamide. For stage 2 of the study, 75 patients had AR expression of at

Table 2. Selected phase II clinical trials of antiandrogen agents in TNBC.

Disease setting	Study, ClinicalTrials.gov identifier	Phase	Drug	Primary endpoint
Metastatic	Bicalutamide for the treatment of patients with AR+, ER-, PR- metastatic BC, NCT00468715	II, open label, single arm	Bicalutamide 150 mg once daily	CBR at 6 months
	Bicalutamide as a treatment in patients with AR+ metastatic TNBC, NCT02348281	II, open label, single arm	Bicalutamide 150 mg once daily	CBR
	Bicalutamide in treating patients with TNBC, NCT02353988	II, open label, single arm	Bicalutamide 150 mg once daily	CBR
	Clinical activity and safety of enzalutamide in patients with advanced AR+ TNBC, stage 2, NCT01889238	II, open label, single arm	Enzalutamide 160 mg once daily	CBR at 16 weeks
	Clinical activity and safety of enzalutamide in patients with advanced AR+ TNBC, stage 1, NCT01889238	II, open label, single arm	Enzalutamide 160 mg once daily	CBR at 16 weeks
	Activity of abiraterone acetate plus prednisone in patients with molecular apocrine HER2- locally advanced or metastatic BC, NCT01842321	II, open label, single arm	Abiraterone acetate 160 mg once daily	CBR at 6 months
	Efficacy and safety of GTx-024 in patients with AR+ TNBC, NCT02368691	II, open label, single arm	GTx-024 18 mg once daily	CBR

AR, androgen receptor; BC, breast cancer; CBR, clinical benefit rate; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; TNBC, triple-negative breast cancer.

least 10% among the 165 patients screened, and the CBR of at least 16 weeks was estimated at 35% with a median PFS of 14.7 weeks.⁹⁸ These promising results have led to the development of the ongoing ENDEAR phase III trial. This study is evaluating the efficacy and safety of enzalutamide, as monotherapy or in combination with paclitaxel chemotherapy, in patients with locally advanced or metastatic TNBC [ClinicalTrials.gov identifier: NCT02677896].

Inhibition of C-kit. Several studies have investigated the expression of C-kit in breast cancers and have observed different percentages of expression of 11–31% of BL breast cancers.^{1,99,100} This overexpression of C-kit implied that these patients might potentially benefit from tyrosine kinase inhibitors (TKIs). However, there is no correlation between the overexpression of C-kit in TNBC and the activating mutations in C-kit and PDGFRA gene. It explains why only a few patients achieve a response to imatinib.^{101,102}

A Chinese study that included 171 patients with TNBC has shown 42.1% of C-kit overexpression but only one activating mutation was detected.¹⁰³ Further investigations among larger and more

heterogeneous populations are required to select patients who can benefit from targeting c-kit in TNBC. Dasatinib is another small molecule that inhibits not only the src and abl kinases but also the C-kit, and could be a potential molecular targeted drug for C-kit-positive TNBC.¹⁰⁴

Inhibition of the JAK2/STAT3 pathway. Janus kinases (JAKs) are tyrosine kinases that activate STAT3 proteins, which are involved in regulation of cell growth, survival, angiogenesis and immunosuppression. The JAK-STAT signaling pathway is frequently deregulated in several cancers, including BL breast cancer, and subsequently may be an effective clinical strategy to treat TNBC.¹⁰⁵

TCGA reports have shown a high rate of JAK2 amplifications among women with TNBC who received preoperative chemotherapy compared with women with primary untreated BL breast cancers.⁴ Consequently, inhibition of the JAK pathway could be promising in the subgroup of patients with JAK2-amplified residual disease. An ongoing phase II study is evaluating the combination of ruxolitinib with preoperative chemotherapy for triple-negative inflammatory breast cancer

[Clinical Trials.gov identifier: NCT02041429]. The trial is evaluating the expression of pSTAT3 and expects a decrease in its expression after treatment. Ruxolitinib is also being evaluated in a phase II trial comparing the OS of women with advanced or metastatic HER2-negative breast cancer who receive treatment with capecitabine in combination with ruxolitinib *versus* those who receive treatment with capecitabine alone [Clinical Trials.gov identifier: NCT02120417].

Inhibition of notch signaling. Studies have shown the aberrant activation of notch signaling in breast cancer and its involvement in proliferation, apoptosis and cancer stem cell activity. The high expression of Notch signaling pathway components including Jagged1-2, Dll1, Dll3 and Dll4, Notch receptors, and Hes and Hey target genes have been demonstrated in breast cancer.¹⁰⁶ The activation of notch receptor *via* the interaction between the membrane-bound ligand and notch receptor leads to a conformational change within the negative regulatory region. This results in sequential cleavage by the ADAM17/TACE metalloprotease and γ secretase, which releases the notch intracellular domain (NICD). Finally NICD translocates to the nucleus and then activates the transcriptional process.¹⁰⁷

Based on these findings, the inhibition of Notch signaling may be a promising therapeutic option for patients with TNBC. Preclinical data demonstrated that TNBC xenograft models with NOTCH1 rearrangements, retaining the γ -secretase cleavage site, were associated with high levels of activated NOTCH1 and conferred sensitivity to γ -secretase inhibitors.

A phase II study is evaluating the efficacy and safety of an oral γ -secretase inhibitor PF-03084014 as a single treatment in patients with advanced TNBC, harboring genomic alterations in Notch receptors (NA+), and in a smaller subset of patients with advanced TNBC whose tumor tests negative for genomic alterations in Notch receptors (NA-). The primary endpoint is the ORR [ClinicalTrials.gov identifier: NCT02299635]. The same γ -secretase inhibitor is under investigation in the neoadjuvant setting among patients with residual disease after anthracycline and taxane based chemotherapy [ClinicalTrials.gov identifier: NCT02338531].

Targeting Trop-2. Trop-2 is a cell-surface glycoprotein present in limited amounts in normal

human tissues but widely expressed in several epithelial carcinomas.¹⁰⁸ It has a crucial role in the regulation of cell-cell adhesion and has been associated with increased tumor aggressiveness and poor prognosis in breast cancer.¹⁰⁹ It is reported to be expressed in over 80% of cases of TNBC.

IMMU-132 (isactuzumab govitecan) is an antibody-drug conjugate developed by linking approximately eight molecules of an active metabolite of irinotecan SN-38 to an antibody that binds to Trop-2.¹¹⁰ A multicenter phase II trial has evaluated isactuzumab govitecan in 83 patients with metastatic TNBC whose disease has failed to respond to at least two prior therapies.¹¹¹ In April 2016, the preliminary analysis showed a median PFS of 5.6 months and a median OS of 14.3 months, with 60% of patients still alive. The ORR was 31.5% including two complete responses. Isactuzumab govitecan was given at the dose of 10 mg/kg intravenously on days 1 and 8 of a 21-day cycle and was well tolerated with the most common severe adverse effects being diarrhea and low blood counts, but there was no treatment interruption because of toxicity.¹¹¹ In consideration of these results, isactuzumab govitecan was recently granted 'breakthrough' status by the US Food and Drug Administration.

Other molecular targets. Several molecular alterations in metastatic TNBC are currently under investigation as potential therapeutic targets. Sensitivity to MEK inhibition has been demonstrated *in vitro* for cell lines derived from TNBC or BL breast cancers, and TNBC cell lines which are sensitive to MEK inhibitors harbor mutations that affect the Ras/MAPK pathway.^{112,113} The activation of MEK can support the stabilization of c-Myc, and therefore MEK inhibition can induce c-Myc degradation in TNBC but it has been demonstrated that this inhibition can simultaneously induce the activation of receptor tyrosine kinases that can cause resistance to therapy.¹¹⁴ These findings suggest that combining MEK inhibitors with agents targeting receptor tyrosine kinases could be a promising strategy.

HDAC inhibitors are under investigation either as single agents [ClinicalTrials.gov identifier: NCT02623751] or in combination with cisplatin in patients with metastatic TNBC [ClinicalTrials.gov identifier: NCT02393794]. Additional molecular targets of interest include c-Met [ClinicalTrials.gov identifier: NCT01738438]¹¹⁵

and hypoxia-inducible factor 1 α (HIF1- α) pathway.¹¹⁶

Role of immunotherapy

Overview of immune gene signature and prognostic implications. Breast cancer was not considered to be an immunogenic cancer, but over recent years, studies have demonstrated the prognostic value and the importance of infiltrating lymphocytes (TILs) in tumors in controlling the clinical progression of numerous cancers, including breast cancer.^{117,118}

Breast cancer subtypes have different degrees of immune infiltration and studies have shown that TNBC and Her2 positive breast cancers are most frequently associated with TILs compared with hormone receptor positive cancer. Subsequently the use of immunotherapy among these patients, especially those with TNBC who express high levels of TILs, could lead to better tumor responses.^{119,120}

Recent studies have revealed that a higher level of TILs (>50%) was associated with worse clinicopathologic features, such as higher grade, higher expression of the proliferation marker Ki-67, and positivity of lymph nodes, but paradoxically, it was associated with better pCR in the neoadjuvant setting in addition to improved PFS and OS in the metastatic setting.^{121–124}

However, research on gene expression profiling has also revealed that TNBC had higher rates of CD8+ T-cell infiltration, which was predictive of good prognosis.¹²⁵ Similarly, intratumoral B cells were found to be associated with favorable outcomes in breast cancer. In contrast, CD4+ T cells, including tumor-associated macrophages and T-regulatory cells, were associated with worse prognosis.

The gene expression analysis of Lehman and colleagues has identified six TNBC subtypes, among them the IM subtype which is composed of immune activated and associated signaling components contributed from both the tumor and the infiltrating lymphocytes. This subtype was associated with better outcome (relapse-free survival) in comparison with other TNBC subtypes.¹ The same analysis revealed that the IM subtype presented higher expression of PDL1, PD1 and CTLA4 that may be attractive targets for checkpoint inhibitors which increase the antitumor

immune response by blocking immune-regulating proteins that downregulate the immune system.

CTLA4 plays a crucial role in normal immunologic homeostasis by regulating immune responses early in T-cell activation. Then its inhibition by ipilimumab does not allow the T cell to interact with the receptor *via* CD28 on its cell surface. CTLA4 enhances the antitumor activity of CD8+ T cells, increases the ratio of CD8+ T cells to Foxp3+ T regulatory cells, and inhibits the suppressive function of T-regulatory cells.¹²⁶

PD1 negatively regulates T-cell activity by blocking T cells and modulating immune responses at different phases. Research evaluating the expression of PD1 in different breast cancer subtypes has found that PD1 was more frequently expressed in TNBC compared with the other subtypes. This immune checkpoint receptor is expressed not only on activated T cells, but also on other lymphocytes, including B cells and natural killer cells, that are all active in the cancer process.^{127,128} PD1 interacts with two ligands, PDL1 and PDL2, and the interaction between PD1 and PDL1 acts to suppress antitumor immunity by exerting a negative regulation on T cells, cytolytic activity and production of cytokine.¹²⁹ PDL1 is expressed in approximately 20–30% of TNBC cases and was found to be associated with TILs, in addition to being correlated with worse clinicopathologic features, such as greater tumor size, higher grade and higher rate of proliferation. These findings suggest that targeting PD1 and PDL1 is a new promising approach in the treatment of TNBC.

Clinical trials of immunotherapy in TNBC. Several trials are ongoing to evaluate the role of immune-checkpoint inhibitors alone or in combination, and of other immunotherapies in TNBC (Table 3).

PD1 monoclonal antibody pembrolizumab was recently evaluated in a single-arm phase IB study that enrolled 32 patients with recurrent or metastatic TNBC. All patients expressed PDL1 and 47% of them had received more than three lines of treatment and 21.9% had received five or more treatments.¹³⁰ Pembrolizumab was administered intravenously at the dose of 10 mg/kg every 2 weeks and was well tolerated, with mainly low-grade joint and muscle pain, fatigue and nausea. Among the 27 patients with measurable disease, one participant (3.7%) had a complete response,

Table 3. Selected phase II or phase III clinical trials of immunotherapy in TNBC.

	Study, ClinicalTrials.gov identifier	Phase	Drug	Primary endpoint
Metastatic	Single-agent pembrolizumab (MK-3475) <i>versus</i> single-agent chemotherapy as per physician's choice for metastatic TNBC, NCT02555657	Phase III, randomized, open label	Pembrolizumab	PFS, OS
	Pembrolizumab (MK-3475) as monotherapy for metastatic TNBC, NCT02447003	Phase II, single arm, open label	Pembrolizumab	ORR, safety
	Nivolumab after induction treatment (four arms: radiotherapy, doxorubicin, cisplatin, cyclophosphamide) or noninduction treatment) in patients with TNBC: TONiC trial, NCT02499367	II, open label, single arm	Nivolumab	PFS
	Atezolizumab (MPDL3280A) (anti-PDL1 antibody) in combination with Nab-paclitaxel compared with placebo with Nab-paclitaxel for patients with previously untreated metastatic TNBC, NCT02425891	Phase III, randomized, open label	Atezolizumab	PFS
Neoadjuvant	Triple-negative first-line study: neoadjuvant trial of Nab-paclitaxel and atezolizumab in patients with TNBC, NCT02530489	II Open-label single-arm	Atezolizumab (anti PD1)	pCR
	Neoadjuvant study with atezolizumab in patients with locally advanced TNBC undergoing treatment with Nab-paclitaxel and carboplatin, NCT02620280	Phase III, randomized, open label	Atezolizumab (anti PD1)	EFS
Adjuvant	Vaccine (DC-CIK)/EC followed by docetaxel, NCT02539017	Phase II	Vaccine (DC-CIK)	DFS, OS

DFS, disease-free survival; EFS, event-free survival; OS, overall survival; ORR, objective response rate; OS, overall survival ; pCR, pathologic complete response; PFS, progression-free survival; TNBC, triple-negative breast cancer.

four participants (14.8%) had a partial response, and 25.9% had stable disease. The median time to response was 18 weeks and the median duration of response had not been reached with a median PFS just under 2 months.¹³⁰

Others studies are currently evaluating pembrolizumab in metastatic and neoadjuvant settings. A phase III trial is testing pembrolizumab *versus* single-agent chemotherapy as per the physician's choice for metastatic TNBC and the primary outcomes are PFS and OS [ClinicalTrials.gov identifier: NCT02555657]. Another PD1 antibody nivolumab is under evaluation in a phase II trial after induction treatment in patients with TNBC (TONIC trial) [ClinicalTrials.gov identifier: NCT02499367].

Inhibition of PDL1 with atezolizumab was tested in a phase I trial in patients with metastatic TNBC. Grade 3–4 toxicities were observed in 8% of patients and immune-related adverse events occurred in a minority of patients. The study reported an ORR of 33% in the nine evaluable patients with one complete response and two

partial responses. All responses were seen within the first 6 weeks of treatment.¹³¹

A neoadjuvant phase III study with atezolizumab is currently ongoing in patients with locally advanced TNBC undergoing treatment with nab-paclitaxel and carboplatin. The primary endpoint is event-free survival [ClinicalTrials.gov identifier: NCT02620280]. Another phase III randomized trial is evaluating atezolizumab with nab-paclitaxel for first-line treatment of patients with locally advanced or metastatic TNBC [ClinicalTrials.gov identifier: NCT02425891].

Another anti-PDL1 agent avelumab was recently evaluated and the study revealed attractive results in the TNBC subgroup. Avelumab produced an improvement in clinical response among patients with PDL1 expression on immune cells estimated at 44.4% *versus* 2.6% in the absence of expression.¹³² Regarding inhibition of CTLA4, a phase I study is currently evaluating tremelimumab, which is an anti-CTLA4 agent, in patients with advanced solid tumors including breast cancer [ClinicalTrials.gov identifier: NCT02527434].

Conclusion

TNBC is a heterogeneous disease characterized by a variety of molecular subtypes, various biologic pathways, with distinct sensitivities to chemotherapy and different clinical outcomes. Standard chemotherapy remains the mainstay of treatment in TNBC, but new targeted therapies and immunotherapeutic agents have shown promising results. The future challenge is to further identify specific targets within subsets of patients diagnosed with TNBC tumors, with the aim of improving the outcome of this aggressive disease.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest statement

The authors declare that there is no conflict of interest.

References

1. Lehmann BD, Bauer JA, Chen X, *et al.* Identification of human triple negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest* 2011; 121: 2750–2767.
2. Dent R, Trudeau M, Pritchard KI, *et al.* Triple-negative breast cancer: clinical features and patterns of recurrence. *Clin Cancer Res* 2007; 13: 4429–4434.
3. Burstein MD, Tsimelzon A, Poage GM, *et al.* Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. *Clin Cancer Res* 2015; 21: 1688–1698.
4. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. *Nature* 2012; 490: 61–70.
5. Mittendorf EA, Philips AV, Meric-Bernstam F, *et al.* PD-L1 expression in triple negative breast cancer. *Cancer Immunol Res* 2014; 2: 361–370.
6. Bauer KR, Brown M, Cress RD, *et al.* Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. *Cancer* 2007; 109: 1721–1728.
7. Lund MJ, Trivers KF, Porter PL, *et al.* Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. *Breast Cancer Res Treat* 2009; 113: 357–370.
8. Stead LA, Lash TL, Sobieraj JE, *et al.* Triple negative breast cancers are increased in black women regardless of age or body mass index. *Breast Cancer Res* 2009; 11: R18.
9. Morris GJ, Naidu S, Topham AK, *et al.* Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. *Cancer* 2007; 110: 876–884.
10. Von Minckwitz G, Untch M, Blohmer JU, *et al.* Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol* 2012; 30: 1796–1804.
11. Carey LA, Dees EC, Sawyer L, *et al.* The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. *Clin Cancer Res* 2007; 13: 2329–2334.
12. Dent R, Trudeau M, Pritchard KI, *et al.* Triple-negative breast cancer: clinical features and patterns of recurrence. *Clin Cancer Res* 2007; 13: 4429–4434.
13. Irvin WJ Jr and Carey LA. What is triple-negative breast cancer? *Eur J Cancer* 2008; 44: 2799–2805.
14. Coughlin SS and Ekwueme DU. Breast cancer as a global health concern. *Cancer Epidemiol* 2009; 33: 315–318.
15. Cleere DW. Triple-negative breast cancer: a clinical update. *Community Oncol* 2010; 7: 203–211.
16. Freedman G, Anderson P, Li T, *et al.* Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. *Cancer* 2009; 115: 946–951.
17. Voduc KD, Cheang MC, Tyldesley S, *et al.* Breast cancer subtypes and the risk of local and regional relapse. *J Clin Oncol* 2010; 28: 1684–1691.
18. Lowery AJ, Kell MR, Glynn RW, *et al.* Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. *Breast Cancer Res Treat* 2012; 133: 831–841.
19. Montagna E, Bagnardi V, Rotmensz N, *et al.* Breast cancer subtypes and outcome after local and regional relapse. *Ann Oncol* 2012; 23: 324–331.

20. Kennecke H, Yerushalmi R, Woods R, *et al.* Metastatic behavior of breast cancer subtypes. *J Clin Oncol* 2010; 28: 3271–3277.
21. Lin NU, Bellon JR and Winer EP. CNS metastases in breast cancer. *J Clin Oncol* 2004; 22: 3608–3617.
22. Heitz F, Harter P, Traut A, *et al.* Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors. *J Clin Oncol* 2008; 26(Suppl. 15): abstract 1010.
23. Harrell JC, Prat A, Parker JS, *et al.* Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. *Breast Cancer Res Treat* 2012; 132: 523–535.
24. Lin NU, Claus E, Sohl J, *et al.* Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous metastases. *Cancer* 2008; 113: 2638–2645.
25. Hammond ME, Hayes DF, Dowsett M, *et al.* American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *J Clin Oncol* 2010; 28: 2784–2795.
26. Goldhirsch A, Ingle JN, Gelber RD, *et al.* Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. *Ann Oncol* 2009; 20: 1319–1329.
27. Wolff AC, Hammond ME, Hicks DG, *et al.*; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *J Clin Oncol* 2013; 31: 3997–4013.
28. Bae SY, Lee SK, Koo MY, *et al.* The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. *Breast Cancer Res Treat* 2011; 126: 471–478.
29. Jung SY, Kim HY, Nam BH, *et al.* Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. *Breast Cancer Res Treat* 2010; 120: 627–637.
30. Reis-Filho JS, Milanezi F, Steele D, *et al.* Metaplastic breast carcinomas are basal-like tumours. *Histopathology* 2006; 49: 10–21.
31. Honma N, Saji S, Kurabayashi R, *et al.* Oestrogen receptor-beta1 but not oestrogen receptor-beta2 is of prognostic value in apocrine carcinoma of the breast. *APMIS* 2008; 116: 923–930.
32. Constantinidou A, Jones RL and Reis-Filho JS. Beyond triple-negative breast cancer: the need to define new subtypes. *Expert Rev Anticancer Ther* 2010; 10: 1197–1213.
33. Nielsen TO, Hsu FD, Jensen K, *et al.* Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. *Clin Cancer Res* 2004; 10(16): 5367–5374.
34. Rakha EA, Reis-Filho JS and Ellis IO. Basal-like breast cancer: a critical review. *J Clin Oncol* 2008; 26: 2568–2581.
35. Gonzalez-Angulo AM, Timms KM, Liu S, *et al.* Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. *Clin Cancer Res* 2011; 17: 1082–1089.
36. Reis-Filho JS and Tutt AN. Triple negative tumours: a critical review. *Histopathology* 2008; 52(1): 108–118.
37. Foulkes WD, Smith IE and Reis-Filho JS. Triple-negative breast cancer. *N Engl J Med* 2010; 363: 1938–1948.
38. Bertucci F, Finetti P, Cervera N, *et al.* How basal are triple-negative breast cancers? *Int J Cancer* 2008; 123: 236–240.
39. Rodriguez-Pinilla SM, Sarrío D, Honrado E, *et al.* Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. *J Clin Pathol* 2007; 60: 1006–1012.
40. Saal LH, Gruvberger-Saal SK, Persson C, *et al.* Recurrent gross mutations of the PTEN tumour suppressor gene in breast cancers with deficient DSB repair. *Nat Genet* 2008; 40: 102–107.
41. Andre F, Job B, Dessen P, *et al.* Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. *Clin Cancer Res* 2009; 15: 441–451.
42. Hu X, Stern HM, Ge L, *et al.* Genetic alterations and oncogenic pathways associated with breast cancer subtypes. *Mol Cancer Res* 2009; 7: 511–522.
43. Han W, Jung EM, Cho J, *et al.* DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. *Genes Chromosomes Cancer* 2008; 47: 490–499.
44. Lehmann BD and Pietenpol JA. Identification and use of biomarkers in treatment strategies for

- triple-negative breast cancer subtypes. *J Pathol* 2014; 232: 142–150.
45. Perou CM. Molecular stratification of triple-negative breast cancers. *Oncologist* 2010; 15(Suppl. 5): 39–48.
 46. Prat A, Parker JS, Karginova O, *et al.* Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. *Breast Cancer Res* 2010; 12: R68.
 47. Curtis C, Shah SP, Chin SF, *et al.* The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* 2012; 486: 346–352.
 48. Dawson SJ, Rueda OM, Aparicio S, *et al.* A new genome-driven integrated classification of breast cancer and its implications. *EMBO J* 2013; 32: 617–628.
 49. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. *Nature* 2001; 411: 366–374.
 50. Hoeijmakers JH and Bootsma D. DNA repair: incisions for excision. *Nature* 1994; 371: 654–655.
 51. Turner N, Tutt A and Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. *Nat Rev Cancer* 2004; 4: 814–819.
 52. Atchley DP, Albarracin CT, Lopez A, *et al.* Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. *J Clin Oncol* 2008; 26: 4282–4288.
 53. Roy R, Chun J and Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. *Nat Rev Cancer* 2011; 12: 68–78.
 54. Castéra L, Krieger S, Rousselin A, *et al.* Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. *Eur J Hum Genet* 2014; 22: 1305–1313
 55. Couch FJ, Hart SN, Sharma P, *et al.* Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. *J Clin Oncol* 2015; 33: 304–311.
 56. Kurian AW, Hare EE, Mills MA, *et al.* Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. *J Clin Oncol* 2014; 32: 2001–2009.
 57. Von Minckwitz G, Schneeweiss A, Loibl S, *et al.* Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. *Lancet Oncol* 2014; 15: 747–756
 58. Sikov WM, Berry DA, Perou CM, *et al.* Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). *J Clin Oncol* 2015; 33: 13–21.
 59. Tian M, Zhong Y, Zhou F, *et al.* Platinum-based therapy for triple-negative breast cancer treatment: a meta-analysis. *Mol Clin Oncol* 2015; 3: 720–724.
 60. NCCN Clinical Practice Guidelines in Oncology. *Breast Cancer* (Version 1. 2017), https://www.nccn.org/professionals/physician_gls/PDF/breast.pdf
 61. Isakoff SJ, Mayer EL, He L, *et al.* TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. *J Clin Oncol* 2015; 33: 1902–1909.
 62. Fan Y, Xu BH, Yuan P, *et al.* Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple negative breast cancer. *Ann Oncol* 2013; 24: 1219–1225.
 63. Hu XC, Zhang J, Xu BH, *et al.* Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol* 2015;16:436–446.
 64. Tutt A, Ellis P, Kilburn L, *et al.* The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). *Paper presented at 2014 San Antonio Breast Cancer Symposium*, December 9–13, 2014; San Antonio, TX. Abstract S3-01.
 65. Tutt A, Robson M, Garber JE, *et al.* Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. *Lancet* 2010; 376: 235–244.
 66. O’Shaughnessy J, Osborne C, Pippen JE, *et al.* Iniparib plus chemotherapy in metastatic triple-negative breast cancer. *N Engl J Med* 2011; 364: 205–214.
 67. O’Shaughnessy J, Schwartzberg LS, Danso MA, *et al.* A randomized phase III study of iniparib


- (BSI-201) in combination with gemcitabine/ carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). *J Clin Oncol* 2011; 29(Suppl.): abstract 1007.
68. Sinha G. Downfall of iniparib: a PARP inhibitor that doesn't inhibit PARP after all. *J Natl Cancer Inst* 2014; 106, djt447.
 69. Patel AG, De Lorenzo SB, Flatten KS, *et al.* Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. *Clin Cancer Res* 2012; 18: 1655–1662.
 70. Tell ML, Jensen KC, Kurian AW, *et al.* PrECOG 0105: final efficacy results from a phase II study of gemcitabine and carboplatin plus iniparib (BSI201) as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer. *J Clin Oncol* 2013; 31(Suppl.): abstract 1003.
 71. Rugo HS, Olopade O, DeMichele A, *et al.* Adaptive randomization of veliparib–carboplatin treatment in breast cancer. *N Engl J Med* 2016; 375: 23–34.
 72. Han HS, Diéras V, Robson M, *et al.* Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. *Paper presented at 2016 39th San Antonio Breast Cancer Symposium*, December 6–10, 2016; San Antonio, TX. Abstract S2-05.
 73. Livraghi L and Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. *BMC Medicine* 2015; 13: 188
 74. Afghahi A, Chang P-J, Ford JM, *et al.* The Talazoparib Beyond BRCA (TBB) trial: A phase II clinical trial of talazoparib (BMN 673) in BRCA1 and BRCA2 wild-type patients with (i) advanced triple-negative breast cancer (TNBC) and homologous recombination deficiency (HRD) as assessed by myriad genetics HRD assay, and (ii) advanced HER2-negative breast cancer (BC) with either a germline or somatic mutation in homologous recombination (HR) pathway genes. *Paper presented at 2013 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium*, December 8–12, 2015; San Antonio, TX. Abstract OT2-05-04.
 75. O'Shaughnessy J, Romieu G, Diéras V, *et al.* Meta-analysis of patients with triple negative breast cancer (TNBC) from three randomized trials of first-line bevacizumab (BV) and chemotherapy treatment for metastatic breast cancer (MBC). *Paper presented at 2010 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium*, December 8–12, 2010; San Antonio, TX. Abstract P6-12-03.
 76. Brufsky A, Valero V, Tiangco B, *et al.* Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): analysis of RIBBON-2. *J Clin Oncol* 2011; 29: (Suppl.): abstract 1010.
 77. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/
 78. Gerber B, Eidtmann H, Rezaei M, *et al.* Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 686 triple-negative primary breast cancers: secondary endpoint analysis of the GeparQuinto study (GBG 44). *J Clin Oncol* 2011; 29(suppl.): abstract 1006.
 79. Bear HD, Tang G, Rastogi P, *et al.* The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. *J Clin Oncol* 2011; 29 (Suppl.): abstract LBA1005.
 80. Cameron D, Brown J, Dent R, *et al.* Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. *Lancet Oncol* 2013; 14: 933–942.
 81. Bergh J, Bondarenko IM, Lichinitser MR, *et al.* First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. *J Clin Oncol* 2012; 30: 921–929.
 82. Barrios CH, Liu MC, Lee SC, *et al.* Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. *Breast Cancer Res Treat* 2010; 121: 121–131.
 83. Baselga J, Segalla JG, Roché H, *et al.* Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. *J Clin Oncol* 2012; 30: 1484–1491.
 84. Baselga J, Zamagni C, Gomez P, *et al.* A phase III randomized, double-blind, trial comparing sorafenib plus capecitabine versus placebo plus capecitabine in the treatment of locally advanced or metastatic HER2-negative breast cancer (RESILIENCE). *ESMO 2014. Ann Oncol* 2014; 25(Suppl. 5): v1–v41.
 85. Corkery B, Crown J, Clynes M, *et al.* Epidermal growth factor receptor as a potential therapeutic

- target in triple-negative breast cancer. *Ann Oncol* 2009; 20: 862–867.
86. Baselga J, Stemmer S, Pego A, *et al.* Cetuximab + cisplatin in estrogen receptor negative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial. *Paper presented at 2010 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium*, December 8–12, 2010, San Antonio, TX. Abstract PD01-01.
 87. Cowherd S, Miller LD, Melin SA, *et al.* A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer. *Cancer Biol Ther* 2015; 16: 678–683.
 88. Yardley DA, Ward PJ, Daniel BR, *et al.* Panitumumab, gemcitabine, and carboplatin as treatment for women with metastatic triple-negative breast cancer: a Sarah Cannon Research Institute phase II trial. *Clin Breast Cancer* 2016; pii: S1526-8209(16)30102-1.
 89. Turner N, Lambros MB, Horlings HM, *et al.* Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. *Oncogene* 2010; 29: 2013–2023.
 90. Banerji S, Cibulskis K, Rangel-Escareno C, *et al.* Sequence analysis of mutations and translocations across breast cancer subtypes. *Nature* 2012; 486: 405–409.
 91. Gonzalez-Angulo A, Green M, Murray J, *et al.* Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) vs the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer. *Ann Oncol* 2014; 25: 1122–1127.
 92. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, *et al.* Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. *Clin Cancer Res* 2009; 15: 2472–2478.
 93. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, *et al.* An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. *Cancer Res* 2008; 68: 6084–6091.
 94. Kumar A, Fernandez-Capetillo O and Carrera AC. Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair. *Proc Natl Acad Sci U S A* 2011; 107: 7491–7496.
 95. Ibrahim YH, Garcia-Garcia C, Serra V, *et al.* PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple negative breast cancer to PARP inhibition. *Cancer Discov* 2012; 2: 1036–1047.
 96. Niemeier LA, Dabbs DJ, Beriwal S, *et al.* Androgen receptor in breast: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. *Mod Pathol* 2010; 23: 205–212.
 97. Gucalp A, Tolaney S, Isakoff SJ, *et al.* Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. *Clin Cancer Res* 2013; 19: 5505–5512.
 98. Traina TA, O’Shaughnessy JO, Nanda R, *et al.* Stage 1 results from MDV3100–11: a 2-stage study of enzalutamide, an androgen receptor inhibitor, in advanced AR_ triple-negative breast cancer. *Paper presented at 2014 37th Annual San Antonio Breast Cancer Symposium*, December 2014; San Antonio, TX. Abstract P5-19-09.
 99. Kim MJ, Ro JY, Ahn SH, *et al.* Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. *Hum Pathol* 2006; 37: 1217–1226.
 100. Lerma E, Peiro G, Ramon T, *et al.* Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). *Mod Pathol* 2007; 20: 1200–1207.
 101. Nalwoga H, Arnes JB, Wabinga H, *et al.* Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women. *APMIS* 2008; 116: 515–525.
 102. Kim MJ, Ro JY, Ahn SH, *et al.* Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. *Hum Pathol* 2006; 37: 1217–1226.
 103. Zhu Y, Wang Y, Guan B, *et al.* C-kit and PDGFRA gene mutations in triple negative breast cancer. *Int J Clin Exp Pathol* 2014; 7: 4280–4285.
 104. Finn RS, Dering J, Ginther C, *et al.* Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. *Breast Cancer Res Treat* 2007; 105: 319–326.

105. Marotta LL, Almendro V, Marusyk A, *et al.* The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors. *J Clin Invest* 2011; 121: 2723–2735.
106. Harrison H, Farnie G, Howell SJ, *et al.* Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. *Cancer Res* 2010; 70: 709–718.
107. Acar A, Simões BM, Clarke RB, *et al.* A role for notch signalling in breast cancer and endocrine resistance. *Stem Cells Int* 2016; 2016: 2498764.
108. Stepan LP, Trueblood ES, Hale K, *et al.* Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. *J Histochem Cytochem* 2011; 59: 701–710.
109. Ambrogio F, Fornili M, Boracchi P, *et al.* Trop-2 is a determinant of breast cancer survival. *PLoS One* 2014; 9: e96993.
110. Goldenberg DM, Vahdat LT, Starodub AN, *et al.* IMMU-132, a potential new antibody-drug conjugate for the treatment of triple-negative breast cancer: preclinical and initial clinical results. *Paper presented at 2014 37th Annual San Antonio Breast Cancer Symposium*, December 9–13, 2014; San Antonio, TX. Abstract P5-19-08.
111. Bardia A, Diamond JR, Messersmith WA, *et al.* Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase II results. *J Clin Oncol* 2016; 34(Suppl.): abstract LBA509.
112. Hoeflich KP, O'Brien C, Boyd Z, *et al.* In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. *Clin Cancer Res* 2009; 15: 4649–4664.
113. Barretina J, Caponigro G, Stransky N, *et al.* The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* 2012; 483: 603–607.
114. Duncan JS, Whittle MC, Nakamura K, *et al.* Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. *Cell* 2012; 149: 307–321.
115. Hu Y, Liu J and Huang H. Recent agents targeting HIF-1 α for cancer therapy. *J Cell Biochem* 2013; 114: 498–509.
116. Sameni M, Tovar EA, Essenburg CJ, *et al.* Cabozantinib (XL184) inhibits growth and invasion of preclinical TNBC models. *Clin Cancer Res* 2016; 22: 923–934.
117. Loi S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. *Oncoimmunology* 2013; 2: e24720.
118. Loi S, Michiels S, Salgado R, *et al.* Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. *Ann Oncol* 2014; 25: 1544–1550.
119. Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, *et al.* The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. *Breast Cancer Res Treat* 2014; 148: 467–476.
120. Adams S, Gray RJ, Demaria S, *et al.* Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. *J Clin Oncol* 2014; 32: 2959–2966.
121. Ono M, Tsuda H, Shimizu C, *et al.* Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. *Breast Cancer Res Treat* 2012; 132: 793–805.
122. Denkert C, Loibl S, Noske A, *et al.* Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. *J Clin Oncol* 2010; 28: 105–113.
123. Denkert C, von MG, Brase JC, *et al.* Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. *J Clin Oncol* 2015; 33: 983–991.
124. Loi S, Sirtaine N, Piette F, *et al.* Prognostic and predictive value of tumor infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. *J Clin Oncol* 2013; 31: 860–867.
125. Liu S, Lachapelle J, Leung S, *et al.* CD8 β lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. *Breast Cancer Res* 2012; 14: R48.

126. Postow MA, Callahan MK and Wolchok JD. Immune checkpoint blockade in cancer therapy. *J Clin Oncol* 2015; 33: 1974–1982.
127. Blank C, Gajewski TF and Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. *Cancer Immunol Immunother* 2005; 54: 307–314.
128. Keir ME, Butte MJ, Freeman GJ, *et al.* PD-1 and its ligands in tolerance and immunity. *Annu Rev Immunol* 2008; 26: 677–704.
129. Butte MJ, Keir ME, Phamduy TB, *et al.* Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. *Immunity* 2007; 27: 111–122.
130. Nanda R, Chow LQ, Dees EC, *et al.* A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Paper presented at 2014 San Antonio Breast Cancer Symposium, December 9–13, 2014; San Antonio, TX. Abstract S1-09.
131. Emens LA, Braiteh FS, Cassier P, *et al.* Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. *Cancer Res* 2015; 75: PD1–PD6.
132. Dirix LY, Takacs I, Nikolinakos P, *et al.* Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase IB JAVELIN solid tumor trial. *Cancer Res* 2016; 76: S1–S4.

Visit SAGE journals online
[journals.sagepub.com/
home/tam](http://journals.sagepub.com/home/tam)

 SAGE journals